CO6741224A2 - Formas cristalinas de un ácido alcoxiimidazol-1-ilmetil bifenil carboxílico - Google Patents

Formas cristalinas de un ácido alcoxiimidazol-1-ilmetil bifenil carboxílico

Info

Publication number
CO6741224A2
CO6741224A2 CO13111802A CO13111802A CO6741224A2 CO 6741224 A2 CO6741224 A2 CO 6741224A2 CO 13111802 A CO13111802 A CO 13111802A CO 13111802 A CO13111802 A CO 13111802A CO 6741224 A2 CO6741224 A2 CO 6741224A2
Authority
CO
Colombia
Prior art keywords
alkoxyimidazol
carboxylic acid
crystalline forms
biphenyl carboxylic
ylmethyl
Prior art date
Application number
CO13111802A
Other languages
English (en)
Inventor
Paul Fatheree
Venkat Thalladi
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of CO6741224A2 publication Critical patent/CO6741224A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formas de sal cristalina de ácido 4’-{2-etoxi-4-etil-5-[((S)-2-mercapto-4-metilpentanoilamino)metil]imidazol-1-ilmetil}-3’-fluoro bifenil-2-carboxílico. La presente invención también proporciona composiciones farmacéuticas que comprenden los compuestos cristalinos, procesos e intermediarios para preparar los compuestos cristalinos, y métodos para usar los compuestos cristalinos para tratar enfermedades tales como la hipertensión.
CO13111802A 2010-11-10 2013-05-03 Formas cristalinas de un ácido alcoxiimidazol-1-ilmetil bifenil carboxílico CO6741224A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41201110P 2010-11-10 2010-11-10

Publications (1)

Publication Number Publication Date
CO6741224A2 true CO6741224A2 (es) 2013-08-30

Family

ID=45003086

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13111802A CO6741224A2 (es) 2010-11-10 2013-05-03 Formas cristalinas de un ácido alcoxiimidazol-1-ilmetil bifenil carboxílico

Country Status (19)

Country Link
US (3) US8362060B2 (es)
EP (1) EP2638017B1 (es)
JP (2) JP2013542258A (es)
KR (1) KR20130130730A (es)
CN (1) CN103189362B (es)
AR (1) AR083828A1 (es)
AU (1) AU2011326622B2 (es)
BR (1) BR112013011715A2 (es)
CA (1) CA2812598A1 (es)
CO (1) CO6741224A2 (es)
ES (1) ES2567721T3 (es)
HK (1) HK1187919A1 (es)
IL (1) IL225303A0 (es)
MX (1) MX2013005165A (es)
NZ (1) NZ609804A (es)
RU (1) RU2013126403A (es)
SG (1) SG189448A1 (es)
TW (1) TW201300366A (es)
WO (1) WO2012064807A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CN106810542B (zh) * 2015-11-30 2021-03-09 苏州开拓药业股份有限公司 一种硫代咪唑烷酮化合物的晶型、盐型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006027680A1 (en) 2004-09-10 2006-03-16 Pfizer Limited 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007106708A2 (en) 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TW201014830A (en) * 2008-09-30 2010-04-16 Theravance Inc Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
TWI545114B (zh) * 2009-09-29 2016-08-11 施萬生物製藥研發Ｉｐ有限責任公司 製備聯苯基咪唑化合物之方法
WO2011109579A1 (en) * 2010-03-04 2011-09-09 Theravance, Inc. Crystalline alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid and methods for preparing thereof

Also Published As

Publication number Publication date
US8362060B2 (en) 2013-01-29
US20120115920A1 (en) 2012-05-10
EP2638017A1 (en) 2013-09-18
BR112013011715A2 (pt) 2017-10-31
AU2011326622A1 (en) 2013-04-04
AR083828A1 (es) 2013-03-27
US9249105B2 (en) 2016-02-02
US20150133518A1 (en) 2015-05-14
MX2013005165A (es) 2013-07-05
HK1187919A1 (zh) 2014-04-17
ES2567721T3 (es) 2016-04-26
EP2638017B1 (en) 2016-01-27
US20130267573A1 (en) 2013-10-10
JP2013542258A (ja) 2013-11-21
AU2011326622B2 (en) 2014-12-18
RU2013126403A (ru) 2014-12-20
IL225303A0 (en) 2013-06-27
CN103189362A (zh) 2013-07-03
KR20130130730A (ko) 2013-12-02
SG189448A1 (en) 2013-05-31
NZ609804A (en) 2015-02-27
CA2812598A1 (en) 2012-05-18
TW201300366A (zh) 2013-01-01
CN103189362B (zh) 2015-03-11
US8802709B2 (en) 2014-08-12
WO2012064807A1 (en) 2012-05-18
JP2016028061A (ja) 2016-02-25

Similar Documents

Publication Publication Date Title
CY1116987T1 (el) Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις
CR20140554A (es) Compuestos de acido dimetil-benzoico
UY33314A (es) Derivados de acido 1-amino-2-ciclopropiletilboronico
ECSP11011517A (es) Compuestos antivirales
EA201590868A1 (ru) Противовирусные соединения
GT201500051A (es) Inhibidores de glucosilceramida sintasa
UY33735A (es) Compuestos antivirales
GT201400034A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
GT201300215A (es) Inhibidores de glucosilceramida sintasa
EA201790963A1 (ru) Противовирусные соединения
EA201490474A1 (ru) Аминохиназолины в качестве ингибиторов киназ
UY31770A1 (es) Inhibidores de catepsina c
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
UA113062C2 (xx) Похідні 5-фтор-4-іміно-3-(заміщеного)-3,4-дигідропіримідин-2(1h)ону
EA201491149A1 (ru) Пиразолопиридиновые производные, способы их получения и их терапевтическое применение
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
CR20160072A (es) Compuestos y composiciones como inhibidores de la mek
TN2015000261A1 (fr) Dérivés d'imidazopyridazine servant de modulateurs des recepteurs gabaa
EA201690844A1 (ru) Ингибиторы gsk-3
EA201400165A1 (ru) Частицы на основе полиакрилата, которые содержат активное соединение
CO6660462A2 (es) Derivados de ácido 3-heteroaroilamino-propiónico sustituidos con oxígeno y su uso como productos farmacéuticos
CO6761373A2 (es) Derivados de ácido 3-heteroaroilamino-propiónico sustituidos y su uso como sustancias farmacéuticas
WO2012104823A3 (en) Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases